1. Neutralizing antibodies to interferon beta in patients with multiple sclerosis

   OriginalPaper Pages: iiI - iiII

2. Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications

   • Hans-Peter Hartung
   • Huub Schellekens
   • Frederick E. Munschauer III

   INTRODUCTION Pages: ii1 - ii3

3. Immunogenicity of recombinant human proteins: causes and consequences

   • Huub Schellekens
   • Nicole Casadevall

   OriginalPaper Pages: ii4 - ii9

4. Biologic role of interferon beta in multiple sclerosis

   • Alfons Billiau
   • Bernd C. Kieseier
   • Hans-Peter Hartung

   OriginalPaper Pages: ii10 - ii14

5. Immunogenicity of interferon beta: differences among products

   • Antonio Bertolotto
   • Florian Deisenhammer
   • Per Sölberg Sørensen

   OriginalPaper Pages: ii15 - ii24

6. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis

   • Timothy Vartanian
   • Per Sölberg Sørensen
   • George Rice

   OriginalPaper Pages: ii25 - ii30

7. Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis

   • Florian Deisenhammer
   • Huub Schellekens
   • Antonio Bertolotto

   OriginalPaper Pages: ii31 - ii39

8. Assessment and management of neutralizing antibodies in patients with multiple sclerosis (Summary/Discussion)

   • Hans-Peter Hartung
   • Frederick E. Munschauer III

   OriginalPaper Pages: ii40 - ii42